SCHEMBL19974930

SCHEMBL19974930

O=C(O)C(CC1CCC1)NCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.50
HPGD P15428 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
USP2 O75604 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MME P08473 1/20 0.46
ACE P12821 1/20 0.46
CPA1 P15085 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
MMP1 P03956 3/20 0.45
FCER2 P06734 2/20 0.45
KLK7 P49862 1/20 0.43
KLKB1 P03952 1/20 0.43
GRN P28799 1/20 0.43
SORT1 Q99523 1/20 0.43
CTSL P07711 2/20 0.42
CTSB P07858 2/20 0.42
CTSS P25774 2/20 0.42
CTSK P43235 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23004918 0.95 LTA4H (0.55) LTA4HHPGDNPC1RAB9AMME
SCHEMBL11896295 0.95 LTA4H (0.55) LTA4HHPGDNPC1RAB9AMME
SCHEMBL11896293 0.95 LTA4H (0.55) LTA4HHPGDNPC1RAB9AMME
SCHEMBL12861564 0.86 ALDH1A1 (0.42) LTA4HHPGDNPC1RAB9AUSP2
SCHEMBL23022995 0.84 MMP1 (0.56) LTA4HHPGDNPC1RAB9AMME
SCHEMBL19974740 0.84 REN (0.46) HPGDNPC1RAB9AUSP2ALDH1A1
Hydrochloric Acid SCHEMBL23005018 0.83 MMP1 (0.55) LTA4HHPGDNPC1RAB9AMME
SCHEMBL23023028 0.82 KLKB1 (0.51) LTA4HHPGDNPC1RAB9AMMP1
SCHEMBL3794340 0.82 KLKB1 (0.51) LTA4HHPGDNPC1RAB9AMMP1
Hydrochloric Acid SCHEMBL23004846 0.81 KLKB1 (0.50) LTA4HHPGDNPC1RAB9AMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C LTA4H 171/4885HPGD 1205/4885NPC1 753/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C LTA4H 244/4885HPGD 1156/4885NPC1 1213/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C LTA4H 171/4885HPGD 1205/4885NPC1 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.